**11. Conclusion**

Lung cancer is already a significant problem in our population. It is one of the major causes for cancer mortality in the younger population, even more in the elderly. The aging population will continue to grow and the proportion of elderly with lung cancer will increase in coming decades. Oncologist will have to develop their abilities to better evaluate them and to give them the appropriate treatment for their condition. Actually, no specific assessment tool is proved to be better than other, but we demonstrated the importance of a form of CGA and all his components in the evaluation of these persons.

Many treatment options are available and proved to be effective in the elderly. It can vary from standard treatment, as for younger patient, to more adapted treatment, in regard to the general functional status of the person and his comorbidities.

For patients with early stage disease, surgery remains the treatment of choice with or without adjuvant chemotherapy. When it is not possible, radiation therapy is an excellent alternative, well tolerated with limited side effects. In case of advanced disease, radiation combined or not to chemotherapy is the option, according to the general functional status of the patient. Palliative treatment, either radiation or chemotherapy can also be offered to the elderly patient, according to their symptoms and wishes.

A good evaluation of the patient and realistic goal for treatment remain essential in this population, but treatment decisions based solely on chronological age is no longer acceptable at this time.

### **12. References**


Lung Cancer in Elderly 243

Canadian Cancer Society's Steering committee: Canadian Cancer Statistics 2010. (2010)

Camerini, A. et al. (2010). Phase II of single-agent oral vinorelbine in elderly (> or =70 years)

*Thoracic Surgery*, Vo.10, No.6, (June 2010), pp. 1015-1021, ISSN 1569-9293. Chang, M.Y. et al. (2007). Factors predicting poor survival after resection of stage IA non-

Charlson, M.E. et al. (1987). A new method of classifying prognostic comorbidity in

Cochrane Lung Cancer Group (2000). Chemotherapy for non-small cell lung cancer. Non-

Cudennec, T. et al. (2010). Use of a simplified geriatric evaluation in thoracic oncology. *Lung* 

Crinò, L. et al. (2008). Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients

Dagnault, A. et al (2010). Retrospective study of 81 patients treated with brachytherapy for

Davidoff, A. J. et al. (2010). Chemotherapy and survival benefit in elderly patients with

Dillman, R. O. et al. (1990). A randomized trial of induction chemotherapy plus high-dose

Dominguez-Ventura, A. et al. (2007). Lung cancer in octogenarians : factors affecting long-

Douillard, J. Y et al (2006). Adjuvant vinorelbine plus cisplatin versus observation in

*Cancer*, (February 2010), Vol.67, No2, pp. 232-6, ISSN 0169-5002.

(October 2007), pp. 850-6, ISSN 0022-5223.

No.5, (1987), pp. 373-383, ISSN 0021-9681.

September 2010), pp. 243-7, ISSN 1538-4721.

No2, (August 2007), pp. 370-4, ISSN 1010-7940.

(may 2010), pp. 2191-7, ISSN 0732-183X.

2000,Vol. 2, ISSN 1469-493X.

183X.

1052-6773.

patients with advanced non-small-cell lung cancer and poor performance status. *The Annals of Oncology*, Vol.21, No.6, (June 2010), pp. 1290-95, ISSN 1552-6259. Chaïbi, P. et al. (2010). Influence of geriatric consultation with comprehensive geriatric

assessment on final therapeutic decision in elderly cancer patients. *Critical Reviews in Oncology/Hematology,* Epub ahead of print, (December 2010), ISSN 1040-8428. Chambers, A. et al (2010). In elderly patients with lung cancer is resection justified in terms

of morbidity, mortality and residual quality of life? *Interactive CardioVascular and* 

small cell lung cancer. *Journal of Thoracic Cardiovascular Surgery,* Vol.134, No.4,

longitudinal studies: development and validation. *Journal of Chronic Disease*, Vol. 40,

small Cell Lung Cancer Collaborative Group. *Cochrane Database Systematic Reviews*,

with advanced non-small-cell lung cancer (INVITE): a randomized phase II study. *Journal of Clinical Oncology*, Vol.26, No.26, (September 2010), pp. 4253, ISSN 0732-

endobronchial primary tumor or metastasis. *Brachytherapy,* Vol.9, No.3, (July-

advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, Vol.28, No.13,

radiation versus radiation alone in stage III non-small-cell lung cancer. *New England Journal of Medicine,* Vol.323, No.14, (October 1990), pp. 940-945, ISSN 0028-4793. Dillman, R. O. et al. (1996). Improved survival I stage III non-small-cell lung cancer: seven-

year follow-up of cancer and leukemia group B (CALGB) 8433 trial. *Journal of National Cancer Institute*, Vol. 88, No.17, (September 1996), pp. 1210-1215, ISSN

term survival following resection. *European Journal of Cardiothoracic Surgery*, Vol.32,

patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Novelbine International Trialist Association, Anita): a randomized

Toronto: Canadian Cancer Society, (April 2010), ISSN 0835-2976.


Arriagada, R. et al. (2004). International Adjuvant Lung Cancer Trial Collaborative Group:

Asmis, T. R. et al. (2008). Age and comorbidity as independent prognostic factors in the

Atagi, S. et al. (2000). Phase II trial of daily low-dose carboplatin and thoracic radiotherapy

*Clinical Oncology,* Vol.30, No.2, (February 200), pp. 59-64, ISSN 1465-3621. Atagi, S. et al. (2005). Standard thoracic radiotherapy with or without concurrent daily low-

Avery, E. J., Kessinger, A. & Ganti, A. K. (2009). Therapeutic options for elderly patients

Bach, P.B. et al. (1999). Racial differences in the treatment of early-stage lung cancer. *New* 

Balducci, L. (2000). Geriatric oncology; challenges for the new century. *European Journal of Cancer,* Vol. 36, No. 14, (Septembre 2000), pp. 1741-1754, ISSN 0959-8049. Baumann, P. et al. (2006). Factors important for efficacy of stereotactic body radiotherapy of

Baumann, P. et al. (2009). Outcome in a prospective phase II trial of medically inoperable

Belani C. P. & Fossela F. (2005). Elderly subgroup analysis of a randomized phase III study

Birim, O. et al. (2003). Lung resection for non-small cell lung cancer in patients older than 70:

Bonfili, P. et al. (2009). Hypofractionned radical radiotherapy in elderly patients with

Brokx, H.A. et al. (2007). Surgical treatment for octogenarians with lung cancer: results from

Vol.104, No. 12, pp. 2766-74, (December 2005), ISSN 1097-0142.

No.1, (January 2010), pp. 81-5, ISSN 0169-5002.

(November 2007), pp. 1013-1017, ISSN 1556-0864.

2004), pp. 351-60, ISSN 0028-4793.

(January 2009), pp. 54-59, ISSN 0732-183X.

June 2009), pp. 340-344, ISSN 0305-7372.

0028-4793.

1651-226X.

6259.

ISSN 0732-183X.

cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. *New England Journal of Medicine*, Vol.350, No.4, (January

treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. *Journal of Clinical Oncology*, Vol. 26, No.1,

in elderly patients with locally advanced non-small cell lung cancer. *Japan Journal of* 

dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). *Japan Journal of Clinical Oncology*, Vol.35, No.4, (April, 2005), pp. 195-201, ISSN 1465-3621.

with advanced non-small cell lung cancer. *Cancer Treatment Reviews*, Vol. 35, No.4, (

*England Journal of Medicine,* Vol.341, No.14 , (October 1999), pp. 1198-1205, ISSN

medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. *Acta Oncologica*. Vol.45, No,7, pp. 787-95, ISSN

stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy. *Journal of Clinical Oncology*, Vol. 27, No.20, (July 2010), pp. 3290-3296,

of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for firstline treatment of advanced non-small cell lung carcinoma (TAX326). *Cancer,* 

mortality, morbidity, and late survival compared with the general population. *The Annals of Thoracic Surgery,* Vol.76, No.6, (December 2003), pp. 1796-801, ISSN 1552-

medically inoperable stage I-II non-small-cell lung cancer. *Lung Cancer*, Vol. 67,

a population-based series of 124 patients. *Journal of Thoracic Oncology,* Vol.2, No.11,


Lung Cancer in Elderly 245

Gridelli, C. (2005). Treatment of advanced non-small-cell lung cancer in the elderly: Results

Hayakawa et al. (2001). High-dose radiation therapy for elderly patients with inoperable or

Hensing, T.A. et al. (2003). The impact of age on toxicity, response rate, quality of life and

Hetzel, M. R. et al. (1985). Laser therapy in 100 tracheobronchial tumors. *Thorax*, Vol.40,

Iberti, W. et al. (1995). Chemotherapy in non-small cell lung cancer: A meta-analysis using

Kudoh, S. et al. (2006). Phase III study of docetaxel compared with vinorelbine in elderly

Langer, C. J. et al. (2002). Cisplatin-based therapy for elderly patients with advanced non-

Langer, C. J. et al. (2002). Elderly patients with locally advanced non-small cell lung cancer

Langer, C. J. et al. (2003). Age-specific subanalysis of ECOG 1594; fit elderly patients (70-

Laporte, S. et al. (2007). Meta-analysis comparing docetaxel and vinca-alkaloid in the first-

Lee, S.M. et al. (2010). TOPICAL: Randomized phase III trial of erlotinib compared with

Leong, S.S. et al. (2007).A randomized phase II of single-agent gemcitabine, vinorelbine or

*Society of Clinical Oncology,* ISSN 0732-183X, Chicago, IL, June 2010.

2003), pp. 362-72, ISSN 1052-6773.

2005), pp. 3125-37, ISSN 0732-183X.

No.5, (May 1985). pp. 341-5, ISSN 0040-6376.

29, No.8, (August 1999), pp. 378-81, ISSN 1465-3621.

No.22, (August 2006), pp. 3657-63, ISSN 0732-183X.

*Clinical Oncology*, ISSN 0732-183X, Chicago, IL, May 2003.

81-8, ISSN 0169-5002.

779-88, ISSN 1097-0142.

pp.173-81, ISSN 1052-6773.

ISSN 0732-183X, Orlando, FL, June 2002.

*(ECCO 14),* Barcelona, Spain, September, 2007.

phase III randomized trial. *Journal of National Cancer Institute,* Vol.95, No.5, (March

of an international expert panel. *Journal of Clinical Oncology,* Vol.23, No.13, (May

unresectable non-small cell lung cancer. *Lung cancer*, vol.32, No.1, (April 2001), pp.

survival in patients with advanced, stage IIIB or IV non-small cell lung carcinoma treated with carboplatin and paclitaxel. *Cancer,* Vol. 98, No.4, (August 2003), pp.

updated data on individual patients from 52 randomised clinical trials. *Bristish Medical Journal,* Vol.311, No.7010, (October 1995), pp. 899-909, ISSN 0959-8138. Ikeda, H. et al. (1999). Analysis of 57 nonagerian cancer patients treated by radical

radiotherapy: a survey of eight institutions. *Japan Journal of Clinical Oncology,* Vol.

patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). *Journal of Clinical Oncology*, Vol.24,

small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. *Journal of National Cancer Institute,* Vol.94, No. 3, (February 2002),

benefit from combined modality therapy: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. *Proceeding American Society of Clinical Oncology,*

80yrs) with NSCLC do as well as younger pts (<70). *Proceeding of American Society of* 

line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data. *Presented at the European Cancer Conference 14* 

placebo in chemotherapy-naïve patients with advanced non-small cell lung cancer and unsuitable for first-line chemotherapy (abstract #7504). *Proceeding American* 

docetaxel in patients with advanced non-small cell lung cancer who are poor status

controlled trial. *Lancet Oncology*, Vol. 7, No.9, (September 2006), pp. 719-27, ISSN 1470-2045.


Douillard, J. Y. et al (2007). Comparison of docetaxel- and vinca-alkaloid-based

Earle, C. C. et al. (2001). Effectiveness of chemotherapy for advanced lung cancer in the

Ebi, N. et al. (2008). A phase II trial of gefitinib monotherapy in chemotherapy-naïve

*Thoracic Oncology*, Vol.3, No.10, (October 2008), pp. 1166-71, ISSN 1556-0864. Extermann, M. et al. (2005). Use of comprehensive geriatric assessment in older cancer

Extermann, M. & Hurria, A. (2007). Comprehensive geriatric assessment for older patients

Fairchild, A. et al. (2008). Palliative thoracic radiotherapy for lung cancer: a systematic

Fiorica, F. et al. (2010). Safety and feasibility of radiotherapy treatment in elderly non-small

Frasci, G.et al. (2000). Gemcitabine plus vinorelbine alone in elderly patients with advanced

Fried, L. P. & Hall, W. J. (2008). EDITORIAL: Leading on Behalf of an Aging Society. *Journal of the American Geriatrics Society*, Vol.56, No.10, pp. 1791–95, ISSN 0002-8614. Furuse, K. et al. (1999). Phase III study of concurrent versus sequential thoracic radiotherapy

Gironés, R. et al. (2011). Prognostic impact of comorbidity in elderly lung cancer patients:

Goddwin J. S. & Osborne C. (2004). Factors affecting the diagnosis and treatment of older

Gonzalez-Aragoneses, F. et al. (2009). Lung cancer surgery in the elderly. *Critical Reviews in* 

Gridelli, C. et al. (2003). Chemotherapy for elderly patients with advanced non-small-cell

No.10, (October 2007), pp. 939-946, ISSN 1556 0864.

3, (September 2005), pp. 241-252, ISSN 1040-8428.

(March-April 2010), pp. 185-91, ISSN 0167-4943.

Vol.19, No.4, (February 2001), pp. 1064-70, ISSN 0732-183X.

1470-2045.

ISSN 0732-183X.

ISSN 0732-183X.

pp. 2529-36, ISSN 0732-183X.

13, ISSN 0169-5002.

6, United Kingdom.

1999), pp. 2692-2699, ISSN 0732-183X.

controlled trial. *Lancet Oncology*, Vol. 7, No.9, (September 2006), pp. 719-27, ISSN

chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: a meta-analysis of seven randomized clinical trials. *Journal of Thoracic Oncology,* Vol.2,

elderly: Instrumental variable and propensity analysis. *Journal of Clinical Oncology*,

patients of 75 years or older with advanced non-small cell lung cancer. *Journal of* 

patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). *Critical Reviews in Oncology/Hematology,* Vol. 55, No.

with cancer. *Journal of Clinical Oncology*, Vol. 25, No.14, (May 2007), pp. 1824-31,

review*. Journal of Clinical Oncology,* Vol.26, No24, (August 2004), pp. 4001-4011 ,

cell lung cancer (NSCLC) patients. *Archives of Gerontology and Geriatrics,* Vol*.*5, No.2,

non-small-cell lung cancer. *Journal of Clinical Oncology,* Vol.18, No.13, (July 2000),

in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *Journal of Clinical Oncology.* Vol. 17, No.9, (September

use and comparison of two scores. *Lung Cancer,* Vol. 72, No. 1, (April 2011), pp. 108-

persons with cancer, In: *Comprehensive Geriatric Oncology,* Balducci L., Lyman, G.H., Ershler, W.B. Extermann, M., (Eds), pp. 56-64, Taylor & Francis, ISBN 1-84181-296-

*Oncology/Hematology,*Vol. 71, No. 3, (September 2009), pp. 266-271, ISSN 1040-8428.

lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES)

phase III randomized trial. *Journal of National Cancer Institute,* Vol.95, No.5, (March 2003), pp. 362-72, ISSN 1052-6773.


Lung Cancer in Elderly 247

Palma, D. et al. (2010). Impact of introducing stereotactic lung radiotherapy for elderly

Park, C.H. et al. (In press 2010). Effect of radiotherapy planning complexity on survival of

Pepe, C. et al. (2007).: Adjuvant vinorelbine and cisplatin in elderly patients: National

Pergolizzi, S. et al. (2002). Older people with non small cell lung cancer in clinical stage IIIA

Pignon, J.P. et al. (2006). Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of

Pignon, T. et al. (1998). Age has no impact on acute and late toxicity of curative thoracic

Port, J. et al. (2004). Pulmonary resection for lung cancer in the octogenarian. *Chest,* Vol.126,

Qiao, X. et al. (2003). The role of radiotherapy in treatment of stage I non-small-cell lung cancer. *Lung Cancer, Vol.* 41, Vol.1, (July 2003), pp. 1-11, ISSN 0169-5002. Quoix, E. A. et al. (2010). Weekly paclitaxel combined with monthly carboplatin versus

Ramalingam, S. S. et al. (2008). Outcomes for elderly, advanced-stage non small-cell lung

Repetto, L. et al. (2002). Comprehensive geriatric assessment adds information to Eastern

Riquet, M. et al. (2001). Non-small cell lung cancer: surgical trends as a function of age. *Revue des maladies respiratoires*, Vol.18, suppl.2, (May 2001), IssN 0761-8425. Rocha Lima, C. et al. (2002). Therapy choices among older patients with lung carcinoma: an

Rowell, N. P. & Williams, C. J. (2001). Radical radiotherapy for stage I/II non-small-cell lung

*Clinical Oncology,* Vol.26, No1, (January 2008),pp. 60-5, ISSN 0732-183X. Raz, D.J. et al. (2007). Natural history of stage I non-small cell lung cancer. *Chest,* Vol.132,

*Oncology*, Vol.25, No. 12, (April 2007), pp. 1553-61, ISSN 0732-183X.

*Radiation, Oncology, Biology, Physics*, pp. 1-6, ISSN 0360-3016.

*of Clinical Oncology*, ISSN 0732-183X,Atlanta, GA, June 2006.

No.3, (September 2004), pp. 733-738, ISSN 0012-3692.

*Clinical Oncology,* ISSN 0732-183X, Chicago, IL, June 2010.

Vol.1, (July 2007), pp. 193-199, ISSN 0012-3692.

2, (January 2002), pp. 494-502, ISSN 0732-183X.

(January 1994), pp. 181-87, ISSN 1097-0142.

ISSN 0732-183X.

5002.

ISSN 0167 8140.

patients with stage I non-small-cell lung cancer: A population-based time-trend analysis. *Journal of Clinical Oncology*, Vol.28, No.35, (December 2010), pp. 5153-59,

elderly patients with unresected localized lung cancer. *International Journal of* 

Cancer Institute of Canada and Intergroup Study JBR.10. *Journal of Clinical* 

and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study. *Lung Cancer*, Vol.37, N0.2, (August 2002), pp. 201-6, ISSN 0169-

five randomized clinical trials including 4584 patients. *Proceeding of American Society* 

radiotherapy. *Radiotherapy and Oncology*, Vol.46, No.3, (March 1998), pp. 239-48,

single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small-cell lung cancer (NSCLC) *Proceeding American Society of* 

cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. *Journal of* 

Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. *Journal of Clinical Oncology*, Vol. 20, No.

evaluation of two trials of the Cancer and Leukemia Group B. *Cancer*, Vol.94, No.1,

cancer in patients not sufficiently fit for or declining surgery (medically

performance and/or are elderly*. Journal of Thoracic Oncology,* Vol.2, No. 3, (March 2007), pp. 230-6, ISSN 1556-0864.


Lilenbaum, R.C. et al (2005). Single-agent versus combination chemotherapy in advanced

*of Clinical Oncology,* Vol.23, No.1, (January 2005), pp. 190-6, ISSN 0732-183X. Lilenbaum, R. et al. (2007). A randomized phase II trial of two schedules of docetaxel in

Lonardi, F. et al. (2000). Radiotherapy for non-small cell lung cancer in patients aged 75 and

Maione P,et al. (2005). Pretreatment quality of life and functional status assessment

McGarry, R. C. et al. (2005). Stereotactic body irradiation therapy of early-stage non-small-

Mery, C. M. et al. (2005). Similar long-term survival of elderly patients with non-small cell

Morita, K. et al. (1997). Radical radiotherapy for medically inoperable non-small cell lung

Nguyen, B. et al. (1999). The safety and efficacy of gemcitabine plus cisplatin in the elderly

Okami, J. et al. (2009) Pulmonary resection in patients aged 80 years or over with clinical

Onishi, H. et al. (2007). Hypofractionned stereotactic radiotherapy (HypoFXSRT) for stage I

PACE participants. (2008). Shall we operate? Preoperative assessment in elderly cancer

Pallis, A.G. et al. (2010). EORTC task force position paper: Approach to the older cancer

Vol.63, No.4, (November 2005), pp. 1010-5, ISSN 0360-3016.

*Oncology*, Vol.42, No.1, (January 1997), pp. 31-6, ISSN 0167-8140.

2007), pp. 230-6, ISSN 1556-0864.

No.1, (April 2000), pp. 43-50, ISSN 0169-5002.

(October 2005), pp. 6865-72, ISSN 0732-183X.

(October 2009), pp. 1247-1253, ISSN 1556-0864.

245, ISSN 0012-3692.

S94-S100, ISSN 0732-183X.

May, 1999.

1040-8428.

0959-8049.

0864.

performance and/or are elderly*. Journal of Thoracic Oncology,* Vol.2, No. 3, (March

non-small-cell lung cancer ; the Cancer and Leukemia Group B (study 9730). *Journal* 

elderly or poor performance status patients with advanced non-small cell lung cancer. *Journal of Thoracic Oncology,* Vol.2, No.4, (April 2007), pp. 306-11, ISSN 1556-

over: safety, effectiveness and possible impact on survival. *Lung Cancer*, Vol.28,

significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. *Journal of Clinical Oncology*, Vol. 23, No. 28,

cell lung carcinoma: phase I study. *International Journal of Oncology, Biology, Physics*,

lung cancer treated with lobectomy or wedge resection within the Surveillance, Epidemiology, and End results database. *Chest* Vol.128, No.1, (July 2005), pp. 237-

cancer in clinical stage I: a retrospective analysis of 149 patients. *Radiotherapy and* 

chemonaive NCSLC patients (age>=70 years) as compared to those with age <70 years*. Proceeding American Society of Clinical Oncology,* ISSN 0732-183X, Atlanta, GA,

stage I non-small cell lung cancer. *Journal of Thoracic Oncology,* Vol.4, No.10,

non-small cell lung cancer: updated results of 257 patients in a Japanese multiinstutitional study. *Journal of Clinical Oncology*, Vol.2, No.7, supp.3, (July 2007), pp.

patients (PACE) can help. A SIOG surgical task force prospective study. *Critical Reviews in Oncology/Hematology,* Vol. 65, No. 2, (February 2008), pp. 156-163, ISSN

patient. *European Journal of Cancer,* Vol.46, No.9, (June 2010), pp. 1502-1513, ISSN


Lung Cancer in Elderly 249

Sullivan, V. et al. (2005). Advanced age does not exclude lobectomy for non-small cell lung

Sutedja, G. et al. (1994). Fiberoptic bronchoscopic electrosurgery under local anesthesia for

Timmerman, R. et al. (2003). Extracranial stereotactic radioablation: results of a phase I

Timmerman, R. et al. (2006). Excessive toxicity when treating central tumor in a phase II

Timmerman, R. et al. (2010). Stereotactic body radiation therapy for inoperable early-stage lung cancer. *JAMA*, Vol.303, No.11, (March 2010), pp. 1070-6, ISSN 0098-7484. Tombolini, V.et al. (2000). Radiotherapy alone in elderly patients with medically inoperable

Toy, E. et al (2003). Palliative Thoracic radiotherapy for non-small-cell lung cancer: A

Van Meeerbeeck, J.P.; Damhuis, R. A. & Vos de Wael, M. L. (2002). High post-operative risk

Wada, H. et al (1998) Thirty-day operative mortality for thoracotomy in lung cancer. *Journal* 

Waller, D. et al. (2004). Chemotherapy for patients with non-small cell lung cancer: the

Wang, J. et al. (2008). Temporal trends and predictors of perioperative chemotherapy use in

Walsh, D. et al. (1990). Bronchoscopic cryotherapy for advanced bronchial carcinoma.

Weiss, G. J. et al. (2006). Elderly patients benefit from second-line cytotoxic chemotherapy: A

carcinoma. *Chest,* Vol.128, No.4, pp. 2671-2676, ISSN 0012-3692.

*Cancer*, Vol.7, No.6, (May 2006), pp. 401-405, ISSN 1526-7304.

No.5, (November 2003), pp. 1946-55, ISSN 0012-3692.

(November-December 2000), pp. 4829-33, ISSN 0250-7005.

Vol.26, No.1, (July 2004), pp. 173-82, ISSN 1010-7940.

*Thorax*, Vol.45, no.7, (July 1990), pp. 509-513, ISSN 0040-6376.

(January 2008), pp. 382-390, ISSN 0012-3692.

*Thorax,* Vol*.*49, No.12, (December 1994), pp. 1243-46, ISSN 0040 6376. Tibaldi, C. et al. (2006). Second-line chemotherapy with a modified schedule of docetaxel in

2006.

4839, ISSN 0732-183X.

pp. 112-123, ISSN 0277-3732.

4884.

5223.

0732-183X.

*Proceeding American Society of Clinical Oncology,* ISSN 0732-183X, Atlanta, GA, June

rapid palliation n patients with central airway malignancies. A preliminary report.

elderly patients with advanced-stage non-small-cell lung cancer. *Clinical Lung* 

study in medically inoperable stage I non-small cell lung cancer*, Chest* Vol. 124,

study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *Journal of Clinical Oncology*, Vol.24, No.30, (October 2006), pp. 4833-

stage IIIA and IIIB non-small cell lung cancer. *Anticancer Research,* Vol.20, No.6C,

systematic review. *American Journal of Clinical Oncology*, Vol. 26, No.2, (April 2003),

after pneumonectomy in elderly patients with right-sided lung cancer cancer. *Euopean Respiratory Journal*, Vol.19, No.1, (January 2002), pp. 141-145, ISSN2042-

*of Thoracic Cardiovascular Surgery,* Vol. 115, No.1, (January 1998), pp. 70-73, ISSN002-

surgical setting of the Big Lung Trial. *European Journal of Cardiothoracic Surgery*,

elderly patients with resected non-small cell lung cancer. *Cancer*, Vol.112, No.2,

subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. *Journal of Clinical Oncology,* Vol.24, No.27, (September 2006), pp. 4405-4411, ISSN

inoperable): A systematic review. *Thorax* Vol.56, No.8, (August 2001), pp. 628-638, ISSN 0040-6376.


Scagliotti, G.V. et al. (2003). Randomized study of adjuvant chemotherapy for completely

Sause, W. T. (1994). Combination chemotherapy and radiation therapy in lung cancer. *Seminar of Oncology*, Vol.21, No.3, suppl. 6, (June 1994) pp. 72-78, ISSN 0093-7754. Sause, W.T. et al. (2000). Final results of phase III trial in regionally advanced unresectable

Schild, S. E. et al. (2003). North Central Cancer Treatment Group. The outcome of combined-

Schuchert, M. J. et al. (2009). Clinical impact of age on outcomes following anatomic lung

Sigel, K. et al. (2009). Effect of age on survival of clinical stage I non-small-cell lung cancer. A*nnals of surgical Oncology*, Vol.16, No.7, (July 2009), pp.1912-7, ISSN 1068-9265. Sibley, G. S. et al. (1998). Radiotherapy alone for medically inoperable stage I non-small cell

*Biology, Physics*, Vol.40, No.1, (January 1998), pp. 149-54, ISSN 0360-3016. Socinski, M. A. et al. (2007). Treatment of non-small cell lung cancer, stage IV :ACCP

Spiro, S. G, & Porter, J. C. (2002). Lung cancer: Where are we today? Current advances in

*Medicine*, Vol.166, No.9, (November 2002), pp.1166-1196, ISSN 1073-449X. Stout, R. et al. (2000). Clinical and quality of life outcomes in the first United Kingdom

Strauss, G. M. et al. (2004). Randomized clinical trial of adjuvant chemotherapy with

Strauss, G. M. et al. (2006). Adjuvant chemotherapy in stage IB non-small cell lung cancer

*Institute,* Vol.95, no.19, (October 2003), pp. 1453-61, ISSN 1052-6773. San José, S. et al. (2006). Radiation therapy alone in elderly patients with early stage non-

(February 2000), pp. 358-364, ISSN 0012-3692.

*Oncology,* ISSN 0732-183X, Orlando, FL, June 2009.

(September 2007), pp. 277S-289S, ISSN 0012-3692.

ISSN 0040-6376.

0169-5002.

1097-0142.

ISSN 0167-8140.

June 2004.

inoperable): A systematic review. *Thorax* Vol.56, No.8, (August 2001), pp. 628-638,

resected stage I, II, or IIIA non-small-cell lung cancer. *Journal of National Cancer* 

small cell lung cancer. *Lung Cancer,* Vol.52, Vol.2, (May 2006), pp. 149-54, ISSN

non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, a Southwest Oncology Group. *Chest,* Vol. 117. No.2,

modality therapy for stage III non-small cell lung cancer in the elderly. *Journal of Clinical Oncology.* Vol.21, No.17, (September 2003), pp. 3201-3206, ISSN 0732-183X. Schild, S. E. et al. (2005). Results of combined therapy for limited-stage small cell lung

carcinoma in the elderly. *Cancer,* Vol.103, No.11, (June 2005), pp. 2349-54, ISSN

resection for stage I non-small lung cancer. *Proceeding American Society of Clinical* 

lung cancer: the Duke experience. *International Journal of Radiation, Oncology,* 

evidence-based clinical practice guidelines (2nd edition). *Chest,* Vol.132, No.3 suppl.,

staging and nonsurgical treatment. *American Journal of Respiratory Critical Care* 

randomized trial if endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment in inoperable non small cell lung cancer. *Radiotherapy and Oncology*, Vol.56, No.3, (September 2000), pp. 323-327,

paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of a Cancer and Leukemia Group B (CALGB) protocol 9633. *Proceeding American Society of Clinical Oncology,* ISSN 0732-183X, New Orleans, LA,

(NSCLC) : report of a Cancer and Luekemia Group B (CALGB) protocol 9633*.* 

*Proceeding American Society of Clinical Oncology,* ISSN 0732-183X, Atlanta, GA, June 2006.


**16** 

Seung Hun Jang

*Republic of Korea* 

**Prediction of Postoperative Lung Function** 

Lung cancer is the leading cause of cancer death in many counties. Despite significant improvement in chemotherapy and radiotherapy, surgery is still the cornerstone of nonsmall cell lung cancer treatment. The lung cancer is categorized into non-small cell lung cancer or small cell lung cancer according to the histology. The patients with stage IA-IIB non-small cell lung cancer and stage I small cell lung cancer are good candidates for lung resection which can offer the best chance for cure. In a series of 407 individuals with resectable cancer, the 346 who went to thoracotomy had a median survival of 30.9 months compared with 15.6 months in the 57 who did not go to surgery (Loewen, et al. 2007). A part of individuals with stage IIIA non-small cell stage may also be the surgical candidates if they are adequately treated with chemotherapy and/or radiotherapy before and/or after surgery. The long term goals of lung cancer surgery include cancer control improving

Smoking is the important risk factor not only for lung cancer but also for other comorbid diseases such as chronic obstructive pulmonary disease (COPD) and coronary heart disease. The patients with lung cancer and COPD have reduced ability to tolerate further losses in lung function. Because of relatively high incidence of postoperative complications, the hospital mortality, as well as disappointing long-term survival after surgical resection of lung cancer, the appropriate selection of patients for pulmonary resection is a continuing challenge. It was reported that only about 30% of individuals with lung cancer were determined to be candidates for lung resection because of the advanced stage (Damhuis & Schutte 1996). In addition, a report showed that 37% of individuals who present with anatomically resectable disease deemed not to be surgical candidates based on poor lung function alone (Baser, et al. 2006). If a patient is deemed a candidate for surgery, it must be realized that pulmonary function will be affected by the resection. The decline in lung function varies with the extent of the resection. Accordingly, it is important to be informed about the risk factors and how they affect postoperative morbidity, mortality, and long-term

Pulmonary function measures such as the forced expiratory volume in one second (FEV1) and the diffusing capacity for carbon monoxide (DLco) are useful predictors of postoperative outcome (Bousamra, et al. 1996; Ferguson, et al. 1988; Markos, et al. 1989). Postoperative value of FEV1 is certainly the most widely used parameter for preoperative risk stratification. It has been shown to be an independent predictor of complications including mortality (Kearney, et al. 1994; Mitsudomi, et al. 1996; Ribas, et al. 1998). The

**1. Introduction** 

survival.

survival and quality of life of the patients.

*Division of Pulmonary, Allergy and Critical Care Medicine,* 

*Hallym University Sacred Heart Hospital,* 


< http://www.seer.cancer.gov/statfacts/html/lungb.html>
